These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

236 related items for PubMed ID: 25497068

  • 21. 18F-FDG uptake as a biologic prognostic factor for recurrence in patients with surgically resected non-small cell lung cancer.
    Higashi K, Ueda Y, Arisaka Y, Sakuma T, Nambu Y, Oguchi M, Seki H, Taki S, Tonami H, Yamamoto I.
    J Nucl Med; 2002 Jan; 43(1):39-45. PubMed ID: 11801701
    [Abstract] [Full Text] [Related]

  • 22. 18F-FDG PET for assessment of therapy response and preoperative re-evaluation after neoadjuvant radio-chemotherapy in stage III non-small cell lung cancer.
    Eschmann SM, Friedel G, Paulsen F, Reimold M, Hehr T, Budach W, Langen HJ, Bares R.
    Eur J Nucl Med Mol Imaging; 2007 Apr; 34(4):463-71. PubMed ID: 17103167
    [Abstract] [Full Text] [Related]

  • 23. Prognostic value of preoperative positron emission tomography in resected stage I non-small cell lung cancer.
    Goodgame B, Pillot GA, Yang Z, Shriki J, Meyers BF, Zoole J, Gao F, Dehdashti F, Patterson A, Siegel BA, Govindan R.
    J Thorac Oncol; 2008 Feb; 3(2):130-4. PubMed ID: 18303432
    [Abstract] [Full Text] [Related]

  • 24. Non-small cell lung cancer: FDG PET for nodal staging in patients with stage I disease.
    Farrell MA, McAdams HP, Herndon JE, Patz EF.
    Radiology; 2000 Jun; 215(3):886-90. PubMed ID: 10831716
    [Abstract] [Full Text] [Related]

  • 25. Prognosis of unexpected and expected pathologic N1 non-small cell lung cancer.
    Shin S, Kim HK, Choi YS, Kim K, Kim J, Shim YM.
    Ann Thorac Surg; 2013 Sep; 96(3):969-75; discussion 975-6. PubMed ID: 23916803
    [Abstract] [Full Text] [Related]

  • 26. Stage T1 non-small cell lung cancer: preoperative mediastinal nodal staging with integrated FDG PET/CT--a prospective study.
    Kim BT, Lee KS, Shim SS, Choi JY, Kwon OJ, Kim H, Shim YM, Kim J, Kim S.
    Radiology; 2006 Nov; 241(2):501-9. PubMed ID: 16966480
    [Abstract] [Full Text] [Related]

  • 27. Measurement of tumor volume by PET to evaluate prognosis in patients with advanced non-small cell lung cancer treated by non-surgical therapy.
    Yan H, Wang R, Zhao F, Zhu K, Jiang S, Zhao W, Feng R.
    Acta Radiol; 2011 Jul 01; 52(6):646-50. PubMed ID: 21508201
    [Abstract] [Full Text] [Related]

  • 28. Maximum standardized uptake value from staging FDG-PET/CT does not predict treatment outcome for early-stage non-small-cell lung cancer treated with stereotactic body radiotherapy.
    Burdick MJ, Stephans KL, Reddy CA, Djemil T, Srinivas SM, Videtic GM.
    Int J Radiat Oncol Biol Phys; 2010 Nov 15; 78(4):1033-9. PubMed ID: 20472359
    [Abstract] [Full Text] [Related]

  • 29. FDG-PET in staging lung cancer: how does it change the algorithm?
    Verhagen AF, Bootsma GP, Tjan-Heijnen VC, van der Wilt GJ, Cox AL, Brouwer MH, Corstens FH, Oyen WJ.
    Lung Cancer; 2004 May 15; 44(2):175-81. PubMed ID: 15084382
    [Abstract] [Full Text] [Related]

  • 30. Impact of whole-body ¹⁸F-fluorodeoxyglucose positron emission tomography on therapeutic management of non-small cell lung cancer.
    Heo EY, Yang SC, Yoo CG, Han SK, Shim YS, Kim YW.
    Respirology; 2010 Nov 15; 15(8):1174-8. PubMed ID: 20573060
    [Abstract] [Full Text] [Related]

  • 31. Diagnostic accuracy of 18F-2-deoxy-fluoro-D-glucose positron emission tomography for pN1 lymph nodes in patients with lung cancer.
    Nakagawa M, Hara M, Sakurai K, Ozawa Y, Mizuno A, Tamaki T, Nishio M, Shibamoto Y.
    Acta Radiol; 2009 Jul 15; 50(6):638-44. PubMed ID: 19492198
    [Abstract] [Full Text] [Related]

  • 32. Non-small cell lung cancer: prospective comparison of integrated FDG PET/CT and CT alone for preoperative staging.
    Shim SS, Lee KS, Kim BT, Chung MJ, Lee EJ, Han J, Choi JY, Kwon OJ, Shim YM, Kim S.
    Radiology; 2005 Sep 15; 236(3):1011-9. PubMed ID: 16014441
    [Abstract] [Full Text] [Related]

  • 33. The effect of FDG-PET on the stage distribution of non-small cell lung cancer.
    Morgensztern D, Goodgame B, Baggstrom MQ, Gao F, Govindan R.
    J Thorac Oncol; 2008 Feb 15; 3(2):135-9. PubMed ID: 18303433
    [Abstract] [Full Text] [Related]

  • 34. Occult nodal metastasis in patients with non-small cell lung cancer at clinical stage IA by PET/CT.
    Park HK, Jeon K, Koh WJ, Suh GY, Kim H, Kwon OJ, Chung MP, Lee KS, Shim YM, Han J, Um SW.
    Respirology; 2010 Nov 15; 15(8):1179-84. PubMed ID: 20573058
    [Abstract] [Full Text] [Related]

  • 35. F-18-FDG-PET confined radiotherapy of locally advanced NSCLC with concomitant chemotherapy: results of the PET-PLAN pilot trial.
    Fleckenstein J, Hellwig D, Kremp S, Grgic A, Gröschel A, Kirsch CM, Nestle U, Rübe C.
    Int J Radiat Oncol Biol Phys; 2011 Nov 15; 81(4):e283-9. PubMed ID: 21470782
    [Abstract] [Full Text] [Related]

  • 36. Improved radiologic staging of lung cancer with 2-[18F]-fluoro-2-deoxy-D-glucose-positron emission tomography and computed tomography registration.
    Aquino SL, Asmuth JC, Alpert NM, Halpern EF, Fischman AJ.
    J Comput Assist Tomogr; 2003 Nov 15; 27(4):479-84. PubMed ID: 12886128
    [Abstract] [Full Text] [Related]

  • 37. Changes in 18F-fluorodeoxyglucose and 18F-fluorodeoxythymidine positron emission tomography imaging in patients with non-small cell lung cancer treated with erlotinib.
    Mileshkin L, Hicks RJ, Hughes BG, Mitchell PL, Charu V, Gitlitz BJ, Macfarlane D, Solomon B, Amler LC, Yu W, Pirzkall A, Fine BM.
    Clin Cancer Res; 2011 May 15; 17(10):3304-15. PubMed ID: 21364032
    [Abstract] [Full Text] [Related]

  • 38. Satellite pulmonary nodule in the same lobe (T4N0) should not be staged as IIIB non-small cell lung cancer.
    Bryant AS, Pereira SJ, Miller DL, Cerfolio RJ.
    Ann Thorac Surg; 2006 Nov 15; 82(5):1808-13; discussion 1813-4. PubMed ID: 17062253
    [Abstract] [Full Text] [Related]

  • 39. Positron emission tomography scanning with 2-fluoro-2-deoxy-d-glucose as a predictor of response of neoadjuvant treatment for non-small cell carcinoma.
    Cerfolio RJ, Ojha B, Mukherjee S, Pask AH, Bass CS, Katholi CR.
    J Thorac Cardiovasc Surg; 2003 Apr 15; 125(4):938-44. PubMed ID: 12698159
    [Abstract] [Full Text] [Related]

  • 40. When is it best to repeat a 2-fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography scan on patients with non-small cell lung cancer who have received neoadjuvant chemoradiotherapy?
    Cerfolio RJ, Bryant AS.
    Ann Thorac Surg; 2007 Oct 15; 84(4):1092-7. PubMed ID: 17888953
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 12.